143 related articles for article (PubMed ID: 38641986)
1. Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer.
Marshall CH; Gondek LP; Daniels V; Lu C; Pasca S; Xie J; Markowski MC; Paller CJ; Sena LA; Denmeade SR; Luo J; Antonarakis ES
Prostate; 2024 Jul; 84(10):954-958. PubMed ID: 38641986
[TBL] [Abstract][Full Text] [Related]
2. Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
Gibson CJ; Kim HT; Zhao L; Murdock HM; Hambley B; Ogata A; Madero-Marroquin R; Wang S; Green L; Fleharty M; Dougan T; Cheng CA; Blumenstiel B; Cibulskis C; Tsuji J; Duran M; Gocke CD; Antin JH; Nikiforow S; DeZern AE; Chen YB; Ho VT; Jones RJ; Lennon NJ; Walt DR; Ritz J; Soiffer RJ; Gondek LP; Lindsley RC
J Clin Oncol; 2022 Jan; 40(2):189-201. PubMed ID: 34793200
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Arends CM; Kopp K; Hablesreiter R; Estrada N; Christen F; Moll UM; Zeillinger R; Schmitt WD; Sehouli J; Kulbe H; Fleischmann M; Ray-Coquard I; Zeimet A; Raspagliesi F; Zamagni C; Vergote I; Lorusso D; Concin N; Bullinger L; Braicu EI; Damm F
Leukemia; 2024 Jun; 38(6):1378-1389. PubMed ID: 38637689
[TBL] [Abstract][Full Text] [Related]
4. [Clonal hematopoiesis and solid neoplasms].
Arends CM; Damm F
Inn Med (Heidelb); 2022 Nov; 63(11):1133-1140. PubMed ID: 36149440
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Morice PM; Leary A; Dolladille C; Chrétien B; Poulain L; González-Martín A; Moore K; O'Reilly EM; Ray-Coquard I; Alexandre J
Lancet Haematol; 2021 Feb; 8(2):e122-e134. PubMed ID: 33347814
[TBL] [Abstract][Full Text] [Related]
6. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation.
Oran B; Champlin RE; Wang F; Tanaka T; Saliba RM; Al-Atrash G; Garcia-Manero G; Kantarjian H; Cao K; Shpall EJ; Alousi AM; Mehta RS; Popat U; Futreal A; Takahashi K
Leukemia; 2022 Jan; 36(1):257-262. PubMed ID: 34135465
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR).
Sahu KK; Li H; Mathew Thomas V; Benson M; Boucher K; Gupta S; Kohli M; Swami U; Agarwal N; Maughan BL
Oncologist; 2024 May; 29(5):450-e725. PubMed ID: 38452035
[TBL] [Abstract][Full Text] [Related]
8. Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Gong J; Posadas E; Bhowmick N; Kim H; Daskivich T; Gupta A; Sandler H; Kamrava M; Zumsteg Z; Freedland S; Figlin R
Oncology (Williston Park); 2021 Mar; 35(3):119-125. PubMed ID: 33818052
[TBL] [Abstract][Full Text] [Related]
9. PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development.
Virtanen V; Paunu K; Ahlskog JK; Varnai R; Sipeky C; Sundvall M
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31357527
[TBL] [Abstract][Full Text] [Related]
10. A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions.
Shin TH; Zhou Y; Chen S; Cordes S; Grice MZ; Fan X; Lee BC; Aljanahi AA; Hong SG; Vaughan KL; Mattison JA; Kohama SG; Fabre MA; Uchida N; Demirci S; Corat MAF; Métais JY; Calvo KR; Buscarlet M; Natanson H; McGraw KL; List AF; Busque L; Tisdale JF; Vassiliou GS; Yu KR; Dunbar CE
Blood; 2022 Oct; 140(16):1774-1789. PubMed ID: 35714307
[TBL] [Abstract][Full Text] [Related]
11. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
Steensma DP
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
[TBL] [Abstract][Full Text] [Related]
12. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.
Thol F; Klesse S; Köhler L; Gabdoulline R; Kloos A; Liebich A; Wichmann M; Chaturvedi A; Fabisch J; Gaidzik VI; Paschka P; Bullinger L; Bug G; Serve H; Göhring G; Schlegelberger B; Lübbert M; Kirchner H; Wattad M; Kraemer D; Hertenstein B; Heil G; Fiedler W; Krauter J; Schlenk RF; Döhner K; Döhner H; Ganser A; Heuser M
Leukemia; 2017 Jun; 31(6):1286-1295. PubMed ID: 27881874
[TBL] [Abstract][Full Text] [Related]
14. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
[TBL] [Abstract][Full Text] [Related]
15. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
[TBL] [Abstract][Full Text] [Related]
16. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
Assmus B; Cremer S; Kirschbaum K; Culmann D; Kiefer K; Dorsheimer L; Rasper T; Abou-El-Ardat K; Herrmann E; Berkowitsch A; Hoffmann J; Seeger F; Mas-Peiro S; Rieger MA; Dimmeler S; Zeiher AM
Eur Heart J; 2021 Jan; 42(3):257-265. PubMed ID: 33241418
[TBL] [Abstract][Full Text] [Related]
17. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.
Karpova Y; Wu C; Divan A; McDonnell ME; Hewlett E; Makhov P; Gordon J; Ye M; Reitz AB; Childers WE; Skorski T; Kolenko V; Tulin AV
Biochem Pharmacol; 2019 Sep; 167():149-162. PubMed ID: 30880062
[TBL] [Abstract][Full Text] [Related]
18. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia.
Tanaka T; Morita K; Loghavi S; Wang F; Furudate K; Sasaki Y; Little L; Gumbs C; Matthews J; Daver N; Pemmaraju N; DiNardo CD; Sasaki K; Yilmaz M; Kadia TM; Ravandi F; Konopleva MY; Kantarjian HM; Champlin RE; Al-Atrash G; Garcia-Manero G; Wang SA; Futreal PA; Takahashi K
Blood; 2021 Nov; 138(18):1733-1739. PubMed ID: 34115096
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibition in prostate cancer.
Nientiedt C; Duensing A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing S
Genes Chromosomes Cancer; 2021 May; 60(5):344-351. PubMed ID: 33084183
[TBL] [Abstract][Full Text] [Related]
20. Combined Effects of Clonal Hematopoiesis and Carotid Stenosis on Cardiovascular Mortality.
Jäger R; Hoke M; Mayer FJ; Boden S; Englisch C; Ay C; Kralovics R; Binder CJ
J Am Coll Cardiol; 2024 May; 83(18):1717-1727. PubMed ID: 38692825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
